ArticlePharmaceutical research2026
Biopharmaceutic Assessment of Post-Approval Changes for Azithromycin Immediate Release Tablets Using Predictive In Vitro Dissolution and a Model-Informed Approach.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundPost-approval changes (PACs) in formulations requires a risk assessment of safety and efficacy for extending the product lifecycle. While BCS class I and III are candidates for biowaivers, standard bioequivalence trials are recommended for compounds with controversial classification (i.e., azithromycin). Surrogate techniques, including predictive in vitro dissolution and modeling, have shown their potential in biopharmaceutic assessment of formulations. In this paper, we aimed to assess the risk associated with PACs in azithromycin immediate-release (IR) tablets using a model-informed approach.
methodsTwo bioequivalent bio-batches (test and reference) were compared to a new test formulation. Dissolution was studied in the gastric and predictive in vitro surrogate media. This latter was tailored to azithromycin IR formulations using the reversible non-equilibrium and Mooney's models to calculate surface pH and equivalent phosphate molarities, respectively. A virtual population that matched the bioequivalence study was created using dissolution input and individual pharmacokinetic data. With these, contributions of dissolution and permeation were estimated using a series resistance model, and virtual bioequivalence was tested.
resultsThe new formulation dissolved noticeable faster in gastric media, although dissolution was comparable in surrogate media across formulations. Nonetheless, the series resistance model revealed that dissolution was much faster than transepithelial absorption, indicating absorption is rate-limited by permeability. Bioequivalence simulations supported this result.
conclusionsThe potential of integrating predictive dissolution in a model-informed PACs (MIPACs) approach was demonstrated. However, a waiver of bioequivalence studies for azithromycin may not be justified before evaluating the potential effect of excipient on azithromycin permeability.
Indexed as
Identifiers
41714545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.